Amy Flaxman
Senior Post-Doctoral Researcher
Lab Lead for Enteric pathogen clinical trials
I lead the lab team delivering clinical studies investigating enteric fever, including testing vaccine immunogenicity and efficacy using human challenge models.
Recent publications
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
-
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article
Madhavan M. et al, (2022), EBioMedicine
-
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Journal article
Marchevsky NG. et al, (2022), EBioMedicine, 81
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225